In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Value of heart rate control using Ivabradine in patients with MODS.

Session Poster Session 3

Speaker Mohamed Fakher

Event : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care - CCU, Intensive, and Critical Cardiovascular Care
  • Session type : Poster Session

Authors : M Fakher (Cairo,EG), MA Kamal (Cairo,EG), WS Samy (Cairo,EG), WA Radwan (Cairo,EG)

Authors:
M Fakher1 , MA Kamal1 , WS Samy1 , WA Radwan1 , 1Cairo University, Critical care department - Cairo - Egypt ,

Citation:

Background:
A heart rate higher than 90?beats/min indicates an unfavorable prognosis for patients with sepsis and MODS . We thought to investigate the effect of the pacemaker current (If) inhibitor Ivabradine on heart rate, hemodynamics, and disease severity among patients with sepsis and multi organ dysfunction syndrome 

Purpose:
To evalute the role of ivabradine in managememt of patients with MODS and its effect on outcome

Methods:
In this prospective, controlled, randomized trial, We evaluated 50 patients with sepsis and or multi organ dysfunction syndrome and  sinus rhythm of at least 90?beats/min , informed consent was taken from all patients included in the study then patients were divided into two groups, Group A ;25 patients receiveng the conventional treatment plus Ivabradine (5?mg twice daily) via the enteral route and Group B 25 patients receiveng only conventional treatment.follow up  patients for 30 days was done ,Echocardiography was done to evaluate diastlic dysfunction at day 0 and day 4.

Results:
Our results showed no significant differnce between both groups regarding  age ,gender, demographics and admission hemodynamics and heart rate. After 96 h from ICU admission there  was a significant difference between both groups in  the heart rate reduction ; 24 beats/min(from 118 to 94 beats/min) in the  group B  and  33 beats/min(from 117 to 84 beats/min) in the Ivabradine group Group A ( p ?= ?0.023). 

Ivabradine had an impact on  decreasing diastolic functionon MODS Patients.There was significant improvement in diastolic function at least one grade from base line in the group reciveng Ivabradine (p = 0.038).
There was no difference between the two groups regarding length of hospital stay ,in-hospital mortality or 30 days mortality .

Conclusion:
Use of enteral Ivabradine can reduce elevated heart rate and improve diastolic function in patients with MODS and sepsis but it has no impact on overall survival, length of ICU stay, or days on mechanical ventilation, vasopressors .

Group ( A )

Group ( B )

P value

Count

Percentage

Count

Percentage

P value

In-Hospital mortality

11

44.0%

12

48.0%

0.777

30 Day mortality

4

16.0%

2

8.0%

0.667



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are